vimarsana.com
Home
Live Updates
Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab) : vimarsana.com
Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)
Wellmarker Bio is pleased to sign a clinical collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate a first-in-class treatment with a novel mechanism in
Related Keywords
Seoul ,
Soult Ukpyolsi ,
South Korea ,
United States ,
Korea ,
Dong Hoon Jin ,
Wellmarker Bio ,
Schwierige Zeiten ,
Ulsan College Of Medicine ,
Pharmaventures Ltd ,
Pharmaventures Capital Ltd ,
Prnewswire Wellmarker Bio Co Ltd ,
Korea Drug Development Fund ,
Merck Co Inc ,
Asan Medical Center ,
Wellmarker Bio Co Ltd ,
Merck Sharp Dohme ,
Department Of Convergence Medicine ,
Convergence Medicine ,
Ulsan College ,
Non Small Cell Lung Cancer ,
United Kingdom Based ,
Merck Sharp ,
Pharmaventures Capital ,
Wellmarker ,
Nnounces ,
Linical ,
Trial ,
Collaboration ,
Valuate ,
389 ,
Combination ,
Keytruda ,
Pembrolizumab ,
vimarsana.com © 2020. All Rights Reserved.